167 related articles for article (PubMed ID: 12700894)
21. Farnesyltransferase inhibitors reverse Ras-mediated inhibition of Fas gene expression.
Zhang B; Prendergast GC; Fenton RG
Cancer Res; 2002 Jan; 62(2):450-8. PubMed ID: 11809695
[TBL] [Abstract][Full Text] [Related]
22. The farnesyltransferase inhibitor, FTI-2153, inhibits bipolar spindle formation during mitosis independently of transformation and Ras and p53 mutation status.
Crespo NC; Delarue F; Ohkanda J; Carrico D; Hamilton AD; Sebti SM
Cell Death Differ; 2002 Jul; 9(7):702-9. PubMed ID: 12058275
[TBL] [Abstract][Full Text] [Related]
23. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli.
Law BK; Norgaard P; Moses HL
J Biol Chem; 2000 Apr; 275(15):10796-801. PubMed ID: 10753872
[TBL] [Abstract][Full Text] [Related]
24. The farnesyltransferase inhibitor FTI-277 radiosensitizes H-ras-transformed rat embryo fibroblasts.
Bernhard EJ; Kao G; Cox AD; Sebti SM; Hamilton AD; Muschel RJ; McKenna WG
Cancer Res; 1996 Apr; 56(8):1727-30. PubMed ID: 8620483
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
[TBL] [Abstract][Full Text] [Related]
26. High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors.
Fiordalisi JJ; Johnson RL; Weinbaum CA; Sakabe K; Chen Z; Casey PJ; Cox AD
J Biol Chem; 2003 Oct; 278(43):41718-27. PubMed ID: 12882980
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Ras and related guanosine triphosphate-dependent proteins as a therapeutic strategy for blocking malignant glioma growth: II--preclinical studies in a nude mouse model.
Pollack IF; Bredel M; Erff M; Hamilton AD; Sebti SM
Neurosurgery; 1999 Nov; 45(5):1208-14; discussion 1214-5. PubMed ID: 10549939
[TBL] [Abstract][Full Text] [Related]
28. Neuroblastoma: inhibition of progression (Part II). Basic science in pediatric surgery.
Girgert R; Wittrock J; Schweizer P
Eur J Pediatr Surg; 2001 Dec; 11(6):363-7. PubMed ID: 11807663
[TBL] [Abstract][Full Text] [Related]
29. Farnesyltransferase inhibitors and human malignant pleural mesothelioma: a first-step comparative translational study.
Cesario A; Catassi A; Festi L; Imperatori A; Pericelli A; Galetta D; Margaritora S; Porziella V; Cardaci V; Granone P; Dominioni L; Russo P
Clin Cancer Res; 2005 Mar; 11(5):2026-37. PubMed ID: 15756029
[TBL] [Abstract][Full Text] [Related]
30. Farnesyltransferase inhibitor attenuates methamphetamine toxicity-induced Ras proteins activation and cell death in neuroblastoma SH-SY5Y cells.
Pirompul N; Govitrapong P; Chetsawang B
Neurosci Lett; 2013 Jun; 545():138-43. PubMed ID: 23643986
[TBL] [Abstract][Full Text] [Related]
31. Genetic and pharmacologic identification of Akt as a mediator of brain-derived neurotrophic factor/TrkB rescue of neuroblastoma cells from chemotherapy-induced cell death.
Li Z; Jaboin J; Dennis PA; Thiele CJ
Cancer Res; 2005 Mar; 65(6):2070-5. PubMed ID: 15781614
[TBL] [Abstract][Full Text] [Related]
32. Regulation of beta-amyloid precursor protein expression by brain-derived neurotrophic factor involves activation of both the Ras and phosphatidylinositide 3-kinase signalling pathways.
Ruiz-León Y; Pascual A
J Neurochem; 2004 Feb; 88(4):1010-8. PubMed ID: 14756823
[TBL] [Abstract][Full Text] [Related]
33. Preclinical antitumor activity of BMS-214662, a highly apoptotic and novel farnesyltransferase inhibitor.
Rose WC; Lee FY; Fairchild CR; Lynch M; Monticello T; Kramer RA; Manne V
Cancer Res; 2001 Oct; 61(20):7507-17. PubMed ID: 11606387
[TBL] [Abstract][Full Text] [Related]
34. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor.
van Golen KL; Bao L; DiVito MM; Wu Z; Prendergast GC; Merajver SD
Mol Cancer Ther; 2002 Jun; 1(8):575-83. PubMed ID: 12479217
[TBL] [Abstract][Full Text] [Related]
35. A farnesyl-protein transferase inhibitor induces p21 expression and G1 block in p53 wild type tumor cells.
Sepp-Lorenzino L; Rosen N
J Biol Chem; 1998 Aug; 273(32):20243-51. PubMed ID: 9685373
[TBL] [Abstract][Full Text] [Related]
36. Autocrine interleukin-1beta production in leukemia: evidence for the involvement of mutated RAS.
Beaupre DM; Talpaz M; Marini FC; Cristiano RJ; Roth JA; Estrov Z; Albitar M; Freedman MH; Kurzrock R
Cancer Res; 1999 Jun; 59(12):2971-80. PubMed ID: 10383163
[TBL] [Abstract][Full Text] [Related]
37. A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis.
Barrington RE; Subler MA; Rands E; Omer CA; Miller PJ; Hundley JE; Koester SK; Troyer DA; Bearss DJ; Conner MW; Gibbs JB; Hamilton K; Koblan KS; Mosser SD; O'Neill TJ; Schaber MD; Senderak ET; Windle JJ; Oliff A; Kohl NE
Mol Cell Biol; 1998 Jan; 18(1):85-92. PubMed ID: 9418856
[TBL] [Abstract][Full Text] [Related]
38. Direct tumor lysis by NK cells uses a Ras-independent mitogen-activated protein kinase signal pathway.
Wei S; Gilvary DL; Corliss BC; Sebti S; Sun J; Straus DB; Leibson PJ; Trapani JA; Hamilton AD; Weber MJ; Djeu JY
J Immunol; 2000 Oct; 165(7):3811-9. PubMed ID: 11034387
[TBL] [Abstract][Full Text] [Related]
39. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine.
Sun J; Blaskovich MA; Knowles D; Qian Y; Ohkanda J; Bailey RD; Hamilton AD; Sebti SM
Cancer Res; 1999 Oct; 59(19):4919-26. PubMed ID: 10519405
[TBL] [Abstract][Full Text] [Related]
40. Enhancement of tumor response by farnesyltransferase inhibitor in C3H/HeJ hepatocarcinoma.
Kim J; Seong J; Kim SH
Ann N Y Acad Sci; 2004 Dec; 1030():95-102. PubMed ID: 15659785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
